This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Radius Health Résultats passés
Passé contrôle des critères 0/6
Informations clés
28.6%
Taux de croissance des bénéfices
30.1%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 35.3% |
| Rendement des fonds propres | n/a |
| Marge nette | -30.7% |
| Dernière mise à jour des bénéfices | 30 Jun 2022 |
Mises à jour récentes des performances passées
Recent updates
Radius Recycling Stays In The Scrap Pile
Jul 16Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Ventilation des recettes et des dépenses
Comment Radius Health gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 22 | 223 | -69 | 129 | 121 |
| 31 Mar 22 | 217 | -73 | 127 | 122 |
| 31 Dec 21 | 230 | -70 | 130 | 131 |
| 30 Sep 21 | 228 | -76 | 138 | 128 |
| 30 Jun 21 | 249 | -60 | 134 | 134 |
| 31 Mar 21 | 247 | -87 | 140 | 151 |
| 31 Dec 20 | 239 | -109 | 143 | 159 |
| 30 Sep 20 | 232 | -113 | 144 | 158 |
| 30 Jun 20 | 200 | -136 | 148 | 149 |
| 31 Mar 20 | 191 | -128 | 150 | 131 |
| 31 Dec 19 | 173 | -133 | 155 | 115 |
| 30 Sep 19 | 152 | -149 | 163 | 104 |
| 30 Jun 19 | 133 | -169 | 170 | 100 |
| 31 Mar 19 | 115 | -203 | 179 | 99 |
| 31 Dec 18 | 99 | -221 | 186 | 98 |
| 30 Sep 18 | 72 | -251 | 193 | 97 |
| 30 Jun 18 | 58 | -259 | 197 | 91 |
| 31 Mar 18 | 37 | -259 | 199 | 84 |
| 31 Dec 17 | 22 | -254 | 189 | 81 |
| 30 Sep 17 | 14 | -236 | 167 | 82 |
| 30 Jun 17 | 1 | -224 | 138 | 89 |
| 31 Mar 17 | 0 | -199 | 104 | 97 |
| 31 Dec 16 | 0 | -183 | 80 | 105 |
| 30 Sep 16 | 0 | -163 | 62 | 104 |
| 30 Jun 16 | 0 | -145 | 51 | 95 |
| 31 Mar 16 | 0 | -125 | 40 | 84 |
| 31 Dec 15 | 0 | -102 | 31 | 68 |
Des revenus de qualité: RDUS is currently unprofitable.
Augmentation de la marge bénéficiaire: RDUS is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.
Accélération de la croissance: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Rendement des fonds propres
ROE élevé: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.